These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15236763)

  • 21. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
    Lin JM; Li B; Rimmer E; VanRoey M; Jooss K
    Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.
    Rossi GR; Mautino MR; Awwad DZ; Husske K; Lejukole H; Koenigsfeld M; Ramsey WJ; Vahanian N; Link CJ
    J Immunother; 2008; 31(6):545-54. PubMed ID: 18528300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth.
    Gil-Ad I; Shtaif B; Levkovitz Y; Nordenberg J; Taler M; Korov I; Weizman A
    Oncol Rep; 2006 Jan; 15(1):107-12. PubMed ID: 16328041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB.
    Sharma S; Dominguez AL; Lustgarten J
    Exp Gerontol; 2006 Jan; 41(1):78-84. PubMed ID: 16289924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
    Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
    Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
    Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
    Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
    Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
    Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine.
    Prell RA; Li B; Lin JM; VanRoey M; Jooss K
    Cancer Res; 2005 Mar; 65(6):2449-56. PubMed ID: 15781661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes.
    Rossi GR; Mautino MR; Unfer RC; Seregina TM; Vahanian N; Link CJ
    Cancer Res; 2005 Nov; 65(22):10555-61. PubMed ID: 16288048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppressive effect of Zedoariae rhizoma on pulmonary metastasis of B16 melanoma cells.
    Seo WG; Hwang JC; Kang SK; Jin UH; Suh SJ; Moon SK; Kim CH
    J Ethnopharmacol; 2005 Oct; 101(1-3):249-57. PubMed ID: 16023317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
    Sundstedt A; Celander M; Hedlund G
    Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
    Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
    Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
    J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
    Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
    Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
    Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS
    J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
    Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.
    Yang Y; Yang S; Ye Z; Jaffar J; Zhou Y; Cutter E; Lieber A; Hellström I; Hellström KE
    Cancer Res; 2007 Mar; 67(5):2339-44. PubMed ID: 17332366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific passive immunotherapy of experimental lymphoma. Effects of macrophage toxic drugs.
    Gerlier D; Avice T; Doré JF
    Biomedicine; 1979 Jul; 31(4):106-10. PubMed ID: 226195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2.
    Luo Y; Wen YJ; Ding ZY; Fu CH; Wu Y; Liu JY; Li Q; He QM; Zhao X; Jiang Y; Li J; Deng HX; Kang B; Mao YQ; Wei YQ
    Clin Cancer Res; 2006 Mar; 12(6):1813-9. PubMed ID: 16551866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.